Anderly C. Chueh
Melbourne, VIC, Australia
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications
Activation of CAMK2 by pseudokinase PEAK1 represents a targetable pathway in triple negative breast cancer.
Journal: Nature communications
Published: March 07, 2024
Feed-forward stimulation of CAMK2 by the oncogenic pseudokinase PEAK1 generates a therapeutically "actionable" signalling axis in triple negative breast cancer.
Journal: bioRxiv : the preprint server for biology
Published: February 26, 2024
Integrative Modeling of Signaling Network Dynamics Identifies Cell Type-Selective Therapeutic Strategies for FGFR4-Driven Cancers.
Journal: Cancer research
Published: November 02, 2023
Correction: ATF3 Repression of BCL-XL Determines Apoptotic Sensitivity to HDAC Inhibitors Across Tumor Types.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: September 15, 2023
Author Correction: DUSP5 is methylated in CIMP-high colorectal cancer but is not a major regulator of intestinal cell proliferation and tumorigenesis.
Journal: Scientific reports
Published: February 10, 2023
Pediatric glioma histone H3.3 K27M/G34R mutations drive abnormalities in PML nuclear bodies.
Journal: Genome biology
Published: January 12, 2023
Integrative characterisation of secreted factors involved in intercellular communication between prostate epithelial or cancer cells and fibroblasts.
Journal: Molecular oncology
Published: August 17, 2022
Identification of biological pathways and processes regulated by NEK5 in breast epithelial cells via an integrated proteomic approach.
Journal: Cell communication and signaling : CCS
Published: July 26, 2022
Discovery of a highly potent, selective, orally bioavailable inhibitor of KAT6A/B histone acetyltransferases with efficacy against KAT6A-high ER+ breast cancer.
Journal: Cell chemical biology
Published: July 06, 2022
VEGF-A, VEGFR1 and VEGFR2 single nucleotide polymorphisms and outcomes from the AGITG MAX trial of capecitabine, bevacizumab and mitomycin C in metastatic colorectal cancer.
Journal: Scientific reports
Published: July 02, 2021
Proteomics-based interrogation of the kinome and its implications for precision oncology.
Journal: Proteomics
Published: November 26, 2020
Preclinical small molecule WEHI-7326 overcomes drug resistance and elicits response in patient-derived xenograft models of human treatment-refractory tumors.
Journal: Cell death & disease
Published: April 02, 2020
Last Updated: 09/26/2026